Neoadjuvant immunochemotherapy plus thymalfasin in locally advanced gastric cancer: a prospective clinical trial - PubMed
5 hours ago
- #Neoadjuvant immunochemotherapy
- #Thymalfasin
- #Gastric cancer
- Neoadjuvant immunochemotherapy plus thymalfasin shows promise for locally advanced gastric and gastroesophageal junction (G/EGJ) adenocarcinoma.
- A phase II trial evaluated anti-PD-1 plus SOX immunochemotherapy combined with thymalfasin, achieving a pathological complete response (pCR) in 30.0% of patients and major pathological response (MPR) in 56.7%.
- The treatment resulted in substantial nodal clearance (ypN0 status in 63.3%) and acceptable safety, with any-grade adverse events in 93.3% of patients.
- Peripheral immune profiling indicated dynamic remodeling towards a more focused effector or memory response, and RNA-seq revealed thymalfasin-associated upregulation of genes involved in antigen processing and type I interferon signaling.
- The findings support further randomized trials to confirm the efficacy and safety of this neoadjuvant approach.